BetterLife Pharma (TSE:BETR) has released an update.
BetterLife Pharma Inc. has announced a fully subscribed private placement offering aimed at raising $1.1 million, which will finance the development of their non-hallucinogenic LSD derivative, BETR-001, and support general working capital needs. The investment opportunity includes units priced at $0.15, each comprising a common share and a purchase warrant, with the latter allowing the holder to buy additional shares at $0.20 within two years.
For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.
